Cell Biotech Co., Ltd. (KOSDAQ:049960)
South Korea · Delayed Price · Currency is KRW 16,140
+240 (1.51%)
At close: Aug 11, 2026
Cell Biotech Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 56,494 | 53,126 | 49,913 | 53,787 | 50,526 | 46,873 |
Revenue Growth | 17.44% | 6.44% | -7.20% | 6.46% | 7.79% | 2.83% |
Gross Profit Gross Profit Growth | 41,021 | 38,356 | 35,811 | 38,649 | 37,672 | 35,475 |
Operating Income Operating Income Growth | 9,739 | 7,914 | 6,796 | 2,195 | 6,051 | 7,257 |
Net Income Net Income Growth | 13,407 | 10,125 | 15,127 | 6,304 | 8,281 | 10,383 |
Earnings Per Share EPS Growth | 1959.70 | 1479.45 | 2210.00 | 921.00 | 1201.00 | 1468.00 |
EPS Growth | -3.71% | -33.06% | 139.96% | -23.31% | -18.19% | 226.54% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 94,601 | 93,062 | 87,454 | 70,332 | 65,368 | 57,834 |
Total Debt Total Debt Growth | 293.41 | 425.38 | 1,017 | 1,555 | 958.57 | 826.38 |
Net Cash (Debt) Net Cash Growth | 94,308 | 92,636 | 86,437 | 68,777 | 64,409 | 57,007 |
Net Cash Growth | 6.64% | 7.17% | 25.68% | 6.78% | 12.98% | 6.47% |
Net Cash Per Share Net Cash Per Share Growth | 13784.72 | 13535.60 | 12628.32 | 10049.37 | 9342.06 | 8061.43 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 13,225 | 11,109 | 19,267 | 7,815 | 12,814 | 14,892 |
Capital Expenditures CapEx Growth | -7,249 | -3,105 | -1,129 | -1,552 | -2,368 | -848.59 |
Free Cash Flow Free Cash Flow Growth | 5,975 | 8,004 | 18,138 | 6,264 | 10,445 | 14,044 |
Free Cash Flow Growth | -63.83% | -55.87% | 189.57% | -40.03% | -25.62% | 116.55% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 72.61% | 72.20% | 71.75% | 71.85% | 74.56% | 75.68% |
Operating Margin | 17.24% | 14.90% | 13.62% | 4.08% | 11.98% | 15.48% |
Pretax Margin | 27.38% | 21.18% | 31.27% | 12.79% | 20.13% | 25.79% |
Profit Margin | 23.73% | 19.06% | 30.31% | 11.72% | 16.39% | 22.15% |
FCF Margin | 10.58% | 15.07% | 36.34% | 11.65% | 20.67% | 29.96% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 600.000 | - | - | 450.000 | 450.000 | 450.000 |
Dividend Per Share Growth | 33.33% | - | - | 0% | 0% | 0% |
Dividend Yield | 3.72% | - | - | 4.33% | 3.99% | 2.78% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 12, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 8.01 | 8.86 | 6.46 | 12.18 | 10.50 | 12.84 |
Forward PE | - | 8.16 | 8.16 | 8.16 | 8.16 | 8.16 |
P/FCF Ratio | 17.97 | 11.21 | 5.38 | 12.26 | 8.32 | 9.49 |
PS Ratio | 1.90 | 1.69 | 1.96 | 1.43 | 1.72 | 2.84 |